Chagas disease treatment efficacy markers: experiences from a Phase III study with nifurtimox in children
Determining the success of antitrypanosomal therapy for Chagas disease is challenging, particularly in the chronic phase of the disease, because seropositivity persists for a long time after successful antitrypanosomal treatment and is known to be related to the duration of Trypanosoma cruzi infecti...
Main Authors: | Ulrike Grossmann, Maria-Luisa Rodriguez |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-09-01
|
Series: | Frontiers in Parasitology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fpara.2023.1229467/full |
Similar Items
-
Estudo comparativo controlado com emprego de benznidazole, nifurtimox e placebo, na forma crônica da doença de Chagas, em uma área de campo com transmissão interrompida. I. Avaliação preliminar
by: José Rodrigues Coura, et al.
Published: (1997-04-01) -
Benznidazole biotransformation in rat heart microsomal fraction without observable ultrastructural alterations: comparison to Nifurtimox-induced cardiac effects
by: María Montalto de Mecca, et al.
Published: (2008-09-01) -
Dipyridamole potentiated the trypanocidal effect of nifurtimox and improved the cardiac function in NMRI mice with acute chagasic myocarditis
by: Sonia Santeliz, et al. -
Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease
by: Miriam Rolon, et al.
Published: (2022-08-01) -
Tratamento da fase crônica da doença de Chagas com nifurtimox associado a corticóide
by: Anis Rassi, et al.
Published: (2002-12-01)